

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,348		ATTY. DOCKET NO.: A0848.70005US00	
				FILING DATE: May 9, 2005		CONFIRMATION NO.: 4929	
				APPLICANT: Silence et al.			
				GROUP ART UNIT: 1649		EXAMINER: Gregory S. Emch	
Sheet	1	of	7				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,487,890		Taylor et al.	01-30-1996
		5,672,347		Aggarwal et al.	09-17-1997
		5,843,440		Pouletty et al.	12-01-1998
		5,891,996		Mateo de Acosta del Rio et al.	04-06-1999
		7,300,655		Hansen et al.	11-27-2007
		7,589,180		Old et al.	09-15-2009
		7,598,350		Liu et al.	10-06-2009
		2002-0058033	A1	Raisch et al.	05-16-2002
		2002-0132275	A1	Fidler et al.	09-19-2002
		2004-0219643	A1	Winter et al.	11-4-2004
		2006-0228355	A1	Silence et al.	10-12-2006
		2007-0077249	A1	Silence et al.	04-05-2007
		2007-0178082	A1	Silence et al.	08-02-2007
		2007-0237769	A1	Silence et al.	10-11-2007
		2007-0264253	A1	Liu et al.	11-15-2007
		2009-0022721	A1	Silence et al.	01-22-2009
		2009-0238829	A1	Silence et al.	09-24-2009
		2009-0324512	A1	Silence et al.	12-31-2009
		2010-0003248	A1	Silence et al.	01-07-2010
		2010-0003249	A1	Silence et al.	01-07-2010
		2010-0003253	A1	Laeremans et al.	01-07-2010
		2010-0021459	A1	Silence et al.	01-28-2010
		2010-0040613	A1	Silence et al.	02-18-2010

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0 368 684	B1	Medical Research Council	05-16-1990	
		EP	0 614 984	A2	Miles Inc.	09-14-1994	
		EP	0 954 978	A1	Unilever NV	11-10-1999	Abstract Only

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,348		ATTY. DOCKET NO.: A0848.70005US00	
				FILING DATE: May 9, 2005		CONFIRMATION NO.: 4929	
				APPLICANT: Silence et al.			
				GROUP ART UNIT: 1649		EXAMINER: Gregory S. Emch	
Sheet	2	of	7				

		EP	1 118 669	A1	Unilever PLC	07-25-2001	
							See copy of counterpart application WO 04/003019, cited previously
		EP	1 517 921		Domantis Ltd.	03-30-2005	
		GB	0115841.9		Medical Research Council	06-28-2001	
		WO	90/05144	A1	Medical Research Council	05-17-1990	
		WO	91/01743	A1	Cemu Bioteknik Ab	02-21-1991	
		WO	92/16142	A1	Vital Signals, Inc.	10-01-1992	
		WO	96/34096	A1	Cell Genesys, Inc.	10-31-1996	
		WO	95/10302	A1	Redcell, Inc.	04-20-1995	
		WO	96/34103	A1	Vrije Universiteit Brussel	10-31-1996	
		WO	00/29004	A1	Peptor Ltd.	05-25-2000	
		WO	01/45746	A2	Genentech, Inc.	06-28-2001	
		WO	02/48193	A2	Unilever N.V.	06-20-2002	
		WO	03/035694	A2	Vlaams Interuniversitair Instituut Voor Biotechnologie VZW	05-01-2003	
		WO	2006/059108	A2	Domantis Ltd.	06-08-2006	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		No Author, The Gale Encyclopedia of Medicine. Olendorf et al eds. 1999,1:419.	
		[No Author Listed] Domain antibodies. http://www.domantis.com/domain.htm . Accessed on October 28, 2009.	
		[No Author Listed] Letters from D. Young & Co. regarding opposition to EP 0656946 dated May 18, 2007 and June 5, 2007.	
		[No Author Listed] Letter from D. Young & Co. regarding EP 1 558 650 Third Party Observations dated September 12, 2007.	
		[No Author Listed] Patentee's Letter regarding EP03776677.1 dated December 23, 2005	
		[No Author Listed] Patentee's Letter regarding EP 05076402.6 dated September 25, 2006.	
		[No Author Listed] Immunochemistry. Nankodo Co., Ltd., July 15, 1983 (1st ed.), pp.35-6.	
		Declaration of Professor Roland E. Kontermann. Filed in opposition to EP 1517921. December 3, 2009.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,348	ATTY. DOCKET NO.: A0848.70005US00
				FILING DATE: May 9, 2005	CONFIRMATION NO.: 4929
				APPLICANT: Silence et al.	
				GROUP ART UNIT: 1649	EXAMINER: Gregory S. Emch
Sheet	3	of	7		

	Curriculum Vitae of Professor Roland E. Kontermann.	
	[No Author Listed] Non-Patent Literature cited during the appeal procedure. Reference D54.	
	[No Author Listed] Non-Patent Literature cited during the appeal procedure. Reference D53.	
	Filing of a New Opposition in EP 1 517 921. Filed on March 6, 2007.	
	Notice of Opposition in EP 1 517 921. Filed on March 6, 2007.	
	Reply of the patent proprietor to the notices of opposition dated October 30, 2007.	
	Letter of Opponent dated April 15, 2008 in opposition to EP 1 517 921 and in response to Patentee's Letter of October 30, 2007.	
	Letter of Opponent dated May 28, 2008 in opposition to EP 1 517 921 and in response to Patentee's Letter of October 30, 2007.	
	Letter of Patentee dated October 13, 2008 in EP 1 517 921.	
	Third party observations in the Opposition Proceedings concerning European patent EP 1 517 921 in the name of Domantis Limited. Munich. November 28, 2008.	
	Letter of opponent regarding the opposition procedure filed in the opposition to EP 1 517 921 on March 30, 2009.	
	Annex to Summons to Attend Oral Proceedings dated May 7, 2009.	
	Letter of Patentee regarding the Opposition Procedure for EP 1 517 921 filed May 19, 2009.	
	Official Action concerning European application No. 06 006 277 dated May 29, 2009.	
	Official Action concerning European application No. 03 776 677 dated June 5, 2009.	
	Third party observations in the Opposition Proceedings concerning European patent EP 1 517 921 in the name of Domantis Limited. Munich. June 17, 2009.	
	Third party observations in the Opposition Proceedings concerning European patent EP 1 517 921 in the name of Domantis Limited. Barcelona. September 1, 2009.	
	Third party observations in the Opposition Proceedings concerning European patent EP 1 517 921 in the name of Domantis Limited. Paris. September 4, 2009.	
	Summary of telephone consultation in European Application No. 06 006 277.5, submitted in EP 1 517 921 on September 25, 2009.	
	Letter of Opponent regarding the Opposition Procedure in EP 1 517 921 dated September 25, 2009.	
	Letter of Opponent regarding the Opposition Procedure in EP 1 517 921 filed by opponent. December 10, 2009.	
	Decision Revoking European Patent No. EP 1 517 921. Letter dated April 8, 2010.	
	Annex to the Decision Revoking European Patent No. EP 1 517 921. April 8, 2010.	
	Annex to the Decision Revoking European Patent No. EP 1 517 921 - Opposition. April 8, 2010.	
	Annex to the Decision Revoking European Patent No. EP 1 517 92 - Grounds for the Decision to Revoke European Patent No. EP 1 517 921 filed April 8, 2010.	
	Main Request filed by Patentee on July 30, 2010.	
	Auxiliary Request 1 filed by patentee on July 30, 2010.	
	Auxiliary Request 2 filed by patentee on July 30, 2010.	
	Auxiliary Request 3 filed by patentee on July 30, 2010.	
	Statement of Grounds of Appeal filed by patentee on July 30, 2010.	
	BANIYASH et al., Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,348	ATTY. DOCKET NO.: A0848.70005US00
				FILING DATE: May 9, 2005	CONFIRMATION NO.: 4929
				APPLICANT: Silence et al.	
				GROUP ART UNIT: 1649	EXAMINER: Gregory S. Emch
Sheet	4	of	7		

	to murine IgE. Eur J Immunol. 1984 Sep;14(9):799-807.	
	BARRIOS et al., Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor. J Mol Recognit. 2004 Jul-Aug;17(4):332-8.	
	BIRKETT, Chapter 3: Half-life. In Pharmacokinetics Made Easy. 2004:16-24.	
	CHEN et al., TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.	
	CHEONG et al., Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem Biophys Res Commun. 1990 Dec 31;173(3):795-800.	
	CHUANG et al., Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002 May;19(5):569-77.	
	COCHRAN et al., Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods. 2004 Apr;287(1-2):147-58.	
	CONNELLY, Fully human domain antibody therapeutics: the best of both worlds. Innovations in Pharmaceutical Technology. 2005;42-5.	
	CONRATH et al., Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother. 2001 Oct;45(10):2807-12.	
	CROMBET-RAMOS et al., Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer. 2002 Oct 20;101(6):567-75.	
	DAVIES et al., 'Camelising' human antibody fragments: NMR studies on VH domains. FEBS Lett. 1994 Feb 21;339(3):285-90.	
	DENNIS et al., Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem. 2002 Sep 20;277(38):35035-43. Epub 2002 Jul 15.	
	DESMYTER et al., Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology. J Biol Chem. 2002 Jun 28;277(26):23645-50. Epub 2002 Apr 17.	
	DOLK et al., Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol. 2005 Jan;71(1):442-50.	
	DREJER et al., Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes. 1991 Nov;40(11):1488-95.	
	DUBNOVITSKY et al., Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Mosc). 2000 Sep;65(9):1011-8.	
	FAHRNER et al., Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev. 2001;18:301-27. Review.	
	FRENKEN et al., Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. 2000 Feb 28;78(1):11-21.	
	HAMILTON-WESSLER et al., Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia. 1999 Oct;42(10):1254-63.	
	HARMSSEN et al., Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. Vet Microbiol. 2005 Nov 30;111(1-2):89-98. Epub 2005 Oct 10.	
	HEITNER et al., Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods. 2001 Feb 1;248(1-2):17-30.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,348	ATTY. DOCKET NO.: A0848.70005US00
				FILING DATE: May 9, 2005	CONFIRMATION NO.: 4929
				APPLICANT: Silence et al.	
				GROUP ART UNIT: 1649	EXAMINER: Gregory S. Emch
Sheet	5	of	7		

	HEY et al., Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 2005 Oct;23(10):514-22.	
	HOLLIGER et al., Retargeting serum immunoglobulin with bispecific diabodies. Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol. 1997 Jul;15(7):632-6.	
	HOLT et al., Domain antibodies: proteins for therapy. Trends Biotechnol. 2003 Nov;21(11):484-90.	
	HOOGENBOOM, Mix and match: building manifold binding sites. Nat Biotechnol. 1997 Feb;15(2):125-6.	
	HULME et al., The measurement of renal permeability using labelled macromolecules. Proc R Soc Med. 1966 Jun;59(6):509-12.	
	JANEWAY et al., Immunobiology. 3 rd Edition. 1997. Garland Press. 3:1-3:11	
	JANEWAY et al., Immunobiology: the immune system in health and disease. Third ed., New York: Garland Pub, 1997:2:19-2:20.	
	KANG et al., Anti-EGFR monoclonal antibody Cetuximab binds the EGFR variant III receptor and internalizes phosphorylated receptor on the cell surface. Eur. J. Cancer. 38:S149.	
	KING, Applications and Engineering of Monoclonal Antibodies. Taylor and Francis Ltd, 1998:40-50.	
	KRÜGER et al., Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries. Appl Microbiol Biotechnol. 2006 Oct;72(4):732-7. Epub 2006 Apr 25.	
	LAUWEREYS et al., Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998 Jul 1;17(13):3512-20.	
	MACEWAN, TNF ligands and receptors—a matter of life and death. Br J Pharmacol. 2002 Feb;135(4):855-75.	
	MAMOT et al., Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15;63(12):3154-61.	
	MAURI et al., Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003 Feb 17;197(4):489-501.	
	MIYAJIMA et al., Rat monoclonal anti-murine IgE antibody removes IgE molecules already bound to mast cells or basophilic leukemia cells, resulting in the inhibition of systemic anaphylaxis and passive cutaneous anaphylaxis. Int Arch Allergy Immunol. 2002 May;128(1):24-32.	
	MORELLI et al., Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res. 1996 May 1;56(9):2082-5.	
	MUYLDERMANS et al., Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci. 2001 Apr;26(4):230-5.	
	MUYLDERMANS et al., Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit. 1999 Mar-Apr;12(2):131-40.	
	NILSSON et al., Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr Purif. 1997 Oct;11(1):1-16. Review.	
	NYGREN et al., In vivo stabilization of a human recombinant CD4 derivative by fusion to a serum-albumin-binding receptor. Vaccines. 1991;91:363-8.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,348	ATTY. DOCKET NO.: A0848.70005US00
				FILING DATE: May 9, 2005	CONFIRMATION NO.: 4929
				APPLICANT: Silence et al.	
				GROUP ART UNIT: 1649	EXAMINER: Gregory S. Emch
Sheet	6	of	7		

		PANT et al., Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis. 2006 Dec 1;194(11):1580-8. Epub 2006 Oct 23.	
		PRESTA et al., Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost. 2001 Mar;85(3):379-89.	
		REECK et al., "Homology" in proteins and nucleic acids: a terminology muddle and a way out of it. Cell. 1987 Aug 28;50(5):667.	
		REILLY et al., Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet. 1997 Apr;32(4):313-23. Review.	
		REITER et al., An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. Mol Biol. 1999 Jul 16;290(3):685-98.	
		REITER et al., Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol. 1996 Oct;14(10):1239-45.	
		RHEINNECKER et al., Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol. 1996 Oct 1;157(7):2989-97.	
		RIECHMANN et al., Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods. 1999 Dec 10;231(1-2):25-38.	
		RIEMER et al., Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol Immunol. 2005 May;42(9):1121-4. Epub 2005 Jan 8.	
		ROOVERS et al., Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EGFR Nanobodies. Cancer Immunol Immunother. 2007 Mar;56(3):303-317.	
		ROSENBERG, Effects of protein aggregates: an immunologic perspective. AAPS J. 2006 Aug 4;8(3):E501-7. Review.	
		SAERENS et al., Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol. 2005 Sep 23;352(3):597-607.	
		SCHEURICH et al., Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer. 1986 Jul 15;38(1):127-33.	
		SCHLAEPPI et al., Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor. J Cancer Res Clin Oncol. 1999;125(6):336-42.	
		SILACCI et al., Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics. 2005 Jun;5(9):2340-50.	
		SMITH et al., Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem. 2001 Sep-Oct;12(5):750-6.	
		STÅHL et al., The use of gene fusions to protein A and protein G in immunology and biotechnology. Pathol Biol (Paris). 1997 Jan;45(1):66-76.	
		STANCOVSKI et al., Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8691-5.	
		TERSKIKH et al., "Peptabody": a new type of high avidity binding protein. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1663-8.	
		TIJINK et al., Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,348	ATTY. DOCKET NO.: A0848.70005US00	
				FILING DATE: May 9, 2005	CONFIRMATION NO.: 4929	
				APPLICANT: Silence et al.		
				GROUP ART UNIT: 1649	EXAMINER: Gregory S. Emch	
Sheet	7	of	7			

		through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther. 2008 Aug;7(8):2288-97.	
		VAN DEN BEUCKEN et al., Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J Mol Biol. 2001 Jul 13;310(3):591-601.	
		VAN DER LINDEN et al., Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J Immunol Methods. 2000 Jun 23;240(1-2):185-95.	
		VAN DER VAART et al., Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine. 2006 May 8;24(19):4130-7. Epub 2006 Mar 7.	
		VICKERS, A vaccine against Alzheimer's disease: developments to date. Drugs Aging. 2002;19(7):487-94.	
		WALDMANN et al., The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972 Aug;51(8):2162-74.	
		WESOLOWSKI et al., Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009 Aug;198(3):157-74. Epub 2009 Jun 16.	
		WINKLER et al., Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody. J Immunol. 2000 Oct 15;165(8):4505-14.	
		WITTE et al., Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 1998 Jun;17(2):155-61.	
		ZHU et al., Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs. 1999;17(3):195-212. Review.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.